IL1A and cancer: Controlled release systems using polymeric nano/micro‐particles may provide an appropriate strategy to infuse low levels of IL‐1 ligands (and other cytokines) over a longer period of time to cancer patients and also protect from the deleterious side effects associated with large bolus doses.